CRO braves the public market, files for $100M IPO

Fort Washington, PA-based ReSearch Pharmaceutical Services is braving the rough waters at Nasdaq, filing an IPO designed to raise $100 million. The CRO reports that it garnered $224 million in revenue last year, an increase from the $175 million in grossed in 2008. Last year's net income, though, was only $2.6 million. Cartesian Capital, The Argentum Group and First Analysis have all backed the CRO, which didn't outline either the number of shares it plans to offer or the expected price...